{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:49:35Z","timestamp":1788569375513,"version":"build-2803163510"},"publisher-location":"Cham","reference-count":89,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032214140","type":"print"},{"value":"9783032214157","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-21415-7_17","type":"book-chapter","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:11:24Z","timestamp":1779358284000},"page":"1043-1077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Applications of Theranostics"],"prefix":"10.1007","author":[{"given":"Jonathan","family":"Kuten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"2","key":"17_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1148\/radiol.2017170346","volume":"286","author":"H Jadvar","year":"2018","unstructured":"Jadvar H, Chen X, Cai W, Mahmood U (2018) Radiotheranostics in cancer diagnosis and management. Radiology 286(2):388\u2013400","journal-title":"Radiology"},{"issue":"8","key":"17_CR2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","volume":"19","author":"L Bodei","year":"2022","unstructured":"Bodei L, Herrmann K, Sch\u00f6der H, Scott AM, Lewis JS (2022) Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol 19(8):534\u2013550","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"17_CR3","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","volume":"21","author":"K Herrmann","year":"2020","unstructured":"Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M et al (2020) Radiotheranostics: a roadmap for future development. Lancet Oncol 21(3):e146\u2013ee56","journal-title":"Lancet Oncol"},{"issue":"6","key":"17_CR4","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/S1470-2045(24)00030-5","volume":"25","author":"SE Lapi","year":"2024","unstructured":"Lapi SE, Scott PJH, Scott AM, Windhorst AD, Zeglis BM, Abdel-Wahab M et al (2024) Recent advances and impending challenges for the radiopharmaceutical sciences in oncology. Lancet Oncol 25(6):e236\u2013ee49","journal-title":"Lancet Oncol"},{"issue":"12","key":"17_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103","journal-title":"N Engl J Med"},{"issue":"1","key":"17_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1172\/JCI101276","volume":"21","author":"S Hertz","year":"1942","unstructured":"Hertz S, Roberts A (1942) Radioactive iodine as an indicator in thyroid physiology. V. The use of radioactive iodine in the differential diagnosis of two types of graves\u2019 disease. J Clin Invest 21(1):31\u201332","journal-title":"J Clin Invest"},{"issue":"8","key":"17_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(18)30113-X","volume":"6","author":"M Schlumberger","year":"2018","unstructured":"Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S et al (2018) Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol 6(8):618\u2013626","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"17_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D et al (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368(7):623\u2013632","journal-title":"N Engl J Med"},{"issue":"10","key":"17_CR9","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 20(10):2453\u20132463","journal-title":"J Clin Oncol"},{"issue":"1","key":"17_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1586\/14737140.4.1.18","volume":"4","author":"JW Friedberg","year":"2004","unstructured":"Friedberg JW, Fisher RI (2004) Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin\u2019s lymphoma. Expert Rev Anticancer Ther 4(1):18\u201326","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"17_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.2967\/jnumed.110.085589","volume":"52","author":"NG Schaefer","year":"2011","unstructured":"Schaefer NG, Huang P, Buchanan JW, Wahl RL (2011) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J Nucl Med 52(5):830\u2013838","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"17_CR12","doi-asserted-by":"publisher","first-page":"121s","DOI":"10.2967\/jnumed.120.251934","volume":"61","author":"L Bodei","year":"2020","unstructured":"Bodei L (2020) Somatostatin receptor scintigraphy: blazing in indium and quenching in gallium. J Nucl Med 61(Suppl 2):121s\u2013122s","journal-title":"J Nucl Med"},{"issue":"5","key":"17_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.semnuclmed.2020.05.004","volume":"50","author":"S Basu","year":"2020","unstructured":"Basu S, Parghane RV, Kamaldeep CS (2020) Peptide receptor radionuclide therapy of neuroendocrine tumors. Semin Nucl Med 50(5):447\u2013464","journal-title":"Semin Nucl Med"},{"issue":"2","key":"17_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al (2017) Phase 3 trial of (177)Lu-Dotatate for Midgut neuroendocrine tumors. N Engl J Med 376(2):125\u2013135","journal-title":"N Engl J Med"},{"issue":"12","key":"17_CR15","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A et al (2021) (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752\u20131763","journal-title":"Lancet Oncol"},{"issue":"10446","key":"17_CR16","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL et al (2024) [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 403(10446):2807\u20132817","journal-title":"Lancet"},{"issue":"1","key":"17_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M et al (2015) Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 42(1):5\u201319","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"17_CR18","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S1470-2045(20)30323-5","volume":"21","author":"L Bodei","year":"2020","unstructured":"Bodei L, Sch\u00f6der H, Baum RP, Herrmann K, Strosberg J, Caplin M et al (2020) Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol 21(9):e431\u2013ee43","journal-title":"Lancet Oncol"},{"issue":"5","key":"17_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00259-015-3250-z","volume":"43","author":"L Bodei","year":"2016","unstructured":"Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S et al (2016) Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 43(5):839\u2013851","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"17_CR20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00259-018-3967-6","volume":"45","author":"L Bodei","year":"2018","unstructured":"Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA et al (2018) PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging 45(7):1155\u20131169","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"17_CR21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","volume":"46","author":"WA van der Zwan","year":"2019","unstructured":"van der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J et al (2019) Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 46(3):704\u2013717","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"17_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102141","volume":"93","author":"J Strosberg","year":"2021","unstructured":"Strosberg J, Leeuwenkamp O, Siddiqui MK (2021) Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis. Cancer Treat Rev 93:102141","journal-title":"Cancer Treat Rev"},{"issue":"1137","key":"17_CR23","doi-asserted-by":"publisher","first-page":"20210896","DOI":"10.1259\/bjr.20210896","volume":"95","author":"K Sitani","year":"2022","unstructured":"Sitani K, Parghane R, Talole S, Basu S (2022) The efficacy, toxicity and survival of salvage retreatment PRRT with (177)Lu-DOTATATE in patients with progressive NET following initial course of PRRT. Br J Radiol 95(1137):20210896","journal-title":"Br J Radiol"},{"issue":"11","key":"17_CR24","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.2967\/jnumed.120.258772","volume":"62","author":"RV Parghane","year":"2021","unstructured":"Parghane RV, Bhandare M, Chaudhari V, Ostwal V, Ramaswamy A, Talole S et al (2021) Surgical feasibility, determinants, and overall efficacy of neoadjuvant (177)Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors. J Nucl Med 62(11):1558\u20131563","journal-title":"J Nucl Med"},{"issue":"5","key":"17_CR25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000434723","volume":"103","author":"PG Claringbold","year":"2016","unstructured":"Claringbold PG, Turner JH (2016) Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-Octreotate-Capecitabine-Temozolomide radiopeptide chemotherapy. Neuroendocrinology 103(5):432\u2013439","journal-title":"Neuroendocrinology"},{"key":"17_CR26","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1200\/JCO.2022.40.16_suppl.4122","volume":"40(16_suppl)","author":"N Pavlakis","year":"2022","unstructured":"Pavlakis N, Ransom DT, Wyld D, Sjoquist KM, Wilson K, Gebski V et al (2022) Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-final results. J Clin Oncol 40(16_suppl):4122","journal-title":"J Clin Oncol"},{"issue":"9","key":"17_CR27","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1007\/s00259-019-04389-2","volume":"46","author":"I Goncalves","year":"2019","unstructured":"Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T et al (2019) Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide\/chemoradionuclide therapy (PRRT\/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Eur J Nucl Med Mol Imaging 46(9):1902\u20131910","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"17_CR28","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/cancers13071701","volume":"13","author":"A La Salvia","year":"2021","unstructured":"La Salvia A, Espinosa-Olarte P, Riesco-Martinez MDC, Anton-Pascual B, Garcia-Carbonero R (2021) Targeted cancer therapy: what\u2019s new in the field of neuroendocrine neoplasms? Cancers (Basel) 13(7):1701","journal-title":"Cancers (Basel)"},{"issue":"3","key":"17_CR29","first-page":"502","volume":"47","author":"R Cescato","year":"2006","unstructured":"Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ et al (2006) Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47(3):502\u2013511","journal-title":"J Nucl Med"},{"issue":"17","key":"17_CR30","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/molecules25174012","volume":"25","author":"R Eychenne","year":"2020","unstructured":"Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N (2020) Overview of Radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules 25(17):4012","journal-title":"Molecules"},{"issue":"44","key":"17_CR31","doi-asserted-by":"publisher","first-page":"16436","DOI":"10.1073\/pnas.0607761103","volume":"103","author":"M Ginj","year":"2006","unstructured":"Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X et al (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 103(44):16436\u201316441","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"17_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0022-3565(24)38013-9","volume":"288","author":"MH Perrin","year":"1999","unstructured":"Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW (1999) Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther 288(2):729\u2013734","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"17_CR33","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.2967\/jnumed.111.088922","volume":"52","author":"D Wild","year":"2011","unstructured":"Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC et al (2011) First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 52(9):1412\u20131417","journal-title":"J Nucl Med"},{"issue":"13","key":"17_CR34","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s00259-020-04832-9","volume":"47","author":"S Krebs","year":"2020","unstructured":"Krebs S, O'Donoghue JA, Biegel E, Beattie BJ, Reidy D, Lyashchenko SK et al (2020) Comparison of (68)Ga-DOTA-JR11 PET\/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT\/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 47(13):3047\u20133057","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"23","key":"17_CR35","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1158\/1078-0432.CCR-19-1026","volume":"25","author":"D Reidy-Lagunes","year":"2019","unstructured":"Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK et al (2019) Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-Satoreotide Tetraxetan. Clin Cancer Res 25(23):6939\u20136947","journal-title":"Clin Cancer Res"},{"issue":"1","key":"17_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00259-023-06383-1","volume":"51","author":"D Wild","year":"2023","unstructured":"Wild D, Gr\u00f8nb\u00e6k H, Navalkissoor S, Haug A, Nicolas GP, Pais B et al (2023) A phase I\/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging 51(1):183\u2013195","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"17_CR37","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","volume":"62","author":"RP Baum","year":"2021","unstructured":"Baum RP, Zhang J, Schuchardt C, M\u00fcller D, M\u00e4cke H (2021) First-in-humans study of the SSTR antagonist (177)Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety, and efficacy. J Nucl Med 62(11):1571\u20131581","journal-title":"J Nucl Med"},{"issue":"4","key":"17_CR38","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00259-023-06467-y","volume":"51","author":"SC Ebbers","year":"2024","unstructured":"Ebbers SC, Barentsz MW, de Vries-Huizing DMV, Versleijen MWJ, Klompenhouwer EG, Tesselaar MET et al (2024) Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA). Eur J Nucl Med Mol Imaging 51(4):1121\u20131132","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"17_CR39","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/ph17030354","volume":"17(3)","author":"A Bracigliano","year":"2024","unstructured":"Bracigliano A, Marretta AL, Guerrera LP, Simioli R, Clemente O, Granata V et al (2024) The management of Phaeochromocytomas and Paragangliomas in the era of precision medicine: where are we now? evidence-based systemic treatment options and future cluster oriented perspectives. Pharmaceuticals (Basel) 17(3):354","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"17_CR40","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/jcm12041494","volume":"12","author":"AL Marretta","year":"2023","unstructured":"Marretta AL, Ottaiano A, Iervolino D, Bracigliano A, Clemente O, Di Gennaro F et al (2023) Response to peptide receptor radionuclide therapy in Pheocromocytomas and Paragangliomas: a systematic review and meta-analysis. J Clin Med 12(4):1494","journal-title":"J Clin Med"},{"issue":"9","key":"17_CR41","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","volume":"36","author":"M Bartolomei","year":"2009","unstructured":"Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E et al (2009) Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36(9):1407\u20131416","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"17_CR42","first-page":"29","volume":"22","author":"PE Hartrampf","year":"2020","unstructured":"Hartrampf PE, H\u00e4nscheid H, Kertels O, Schirbel A, Kreissl MC, Flentje M et al (2020) Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol 22:29\u201332","journal-title":"Clin Transl Radiat Oncol"},{"key":"17_CR43","first-page":"S215\u2013s28","volume":"26(Supplement_9","author":"MJ Mair","year":"2024","unstructured":"Mair MJ, Tabouret E, Johnson DR, Sulman EP, Wen PY, Preusser M, Albert NL (2024) Radioligand therapies in meningioma: evidence and future directions. Neuro-Oncology 26(Supplement_9):S215\u2013s28","journal-title":"Neuro-Oncology"},{"issue":"3","key":"17_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Foss\u00e5 SD et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"3","key":"17_CR45","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","volume":"20","author":"M Smith","year":"2019","unstructured":"Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS et al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(3):408\u2013419","journal-title":"Lancet Oncol"},{"issue":"4","key":"17_CR46","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull WE, W\u00e4ngler C, Mier W et al (2012) 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23(4):688\u2013697","journal-title":"Bioconjug Chem"},{"issue":"10231","key":"17_CR47","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208\u20131216","journal-title":"Lancet"},{"issue":"10276","key":"17_CR48","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC et al (2021) [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397(10276):797\u2013804","journal-title":"Lancet"},{"issue":"10459","key":"17_CR49","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN et al (2024) (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404(10459):1227\u20131239","journal-title":"Lancet"},{"issue":"3","key":"17_CR50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen RS, Buteau JP, Jackson P, Mitchell C, Oon SF, Alghazo O et al (2024) Administering [(177)Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-Centre, single-arm, phase 1\/2 study. Eur Urol 85(3):217\u2013226","journal-title":"Eur Urol"},{"issue":"10","key":"17_CR51","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ et al (2024) Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol 25(10):1267\u20131276","journal-title":"Lancet Oncol"},{"issue":"5","key":"17_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A et al (2024) [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 25(5):563\u2013571","journal-title":"Lancet Oncol"},{"key":"17_CR53","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/cancers14040907","volume":"14(4)","author":"A Marchetti","year":"2022","unstructured":"Marchetti A, Rosellini M, Nuvola G, Tassinari E, Mollica V, Rizzo A et al (2022) PARP inhibitors and radiometabolic approaches in metastatic castration-resistant prostate cancer: what\u2019s now, what\u2019s new, and what\u2019s coming? Cancers (Basel) 14(4):907","journal-title":"Cancers (Basel)"},{"key":"17_CR54","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","volume":"41(16_suppl)","author":"S Sandhu","year":"2023","unstructured":"Sandhu S, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R et al (2023) LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 41(16_suppl):5005","journal-title":"J Clin Oncol"},{"key":"17_CR55","doi-asserted-by":"publisher","first-page":"CT224-CT","DOI":"10.1158\/1538-7445.AM2024-CT224","volume":"84(7_Supplement","author":"ES Delpassand","year":"2024","unstructured":"Delpassand ES, Hashmi MJ, Kazakin J, Nawaz O, Garufi G, Schindler J, Nordquist L (2024) Abstract CT224: preliminary efficacy and safety results from the (TATCIST) trial: a PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Cancer Res 84(7_Supplement):CT224-CT","journal-title":"Cancer Res"},{"issue":"8","key":"17_CR56","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2967\/jnumed.124.267650","volume":"65","author":"JP Buteau","year":"2024","unstructured":"Buteau JP, Kostos L, Alipour R, Jackson P, McInstosh L, Emmerson B et al (2024) Clinical trial protocol for VIOLET: a single-Center, phase I\/II trial evaluation of Radioligand treatment in patients with metastatic castration-resistant prostate cancer with [(161)Tb]Tb-PSMA-I&T. J Nucl Med 65(8):1231\u20131238","journal-title":"J Nucl Med"},{"issue":"7","key":"17_CR57","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1200\/JCO.23.00573","volume":"42","author":"ST Tagawa","year":"2024","unstructured":"Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M et al (2024) Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of (225)Ac-J591. J Clin Oncol 42(7):842\u2013851","journal-title":"J Clin Oncol"},{"issue":"13","key":"17_CR58","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1007\/s00259-024-06825-4","volume":"51","author":"F Rosar","year":"2024","unstructured":"Rosar F, Schuler J, Burgard C, Blickle A, Bartholom\u00e4 M, Maus S et al (2024) Efficacy and safety of rechallenge [(177)Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study). Eur J Nucl Med Mol Imaging 51(13):4151\u20134162","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"17_CR59","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2967\/jnumed.123.267321","volume":"65","author":"R Seifert","year":"2024","unstructured":"Seifert R, Telli T, Lapa C, Desaulniers M, Hekimsoy T, Weber WA et al (2024) Safety and efficacy of extended therapy with [(177)Lu]Lu-PSMA: a German multicenter study. J Nucl Med 65(6):909\u2013916","journal-title":"J Nucl Med"},{"issue":"6","key":"17_CR60","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2967\/jnumed.119.236414","volume":"61","author":"J Violet","year":"2020","unstructured":"Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G et al (2020) Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of (177)Lu-PSMA-617 Theranostics in metastatic castration-resistant prostate cancer. J Nucl Med 61(6):857\u2013865","journal-title":"J Nucl Med"},{"issue":"6","key":"17_CR61","first-page":"979","volume":"28","author":"L Von Moll","year":"1987","unstructured":"Von Moll L, McEwan AJ, Shapiro B, Sisson JC, Gross MD, Lloyd R et al (1987) Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med 28(6):979\u2013988","journal-title":"J Nucl Med"},{"key":"17_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104606","volume":"207","author":"F Fabozzi","year":"2025","unstructured":"Fabozzi F, Villani MF, Del Bufalo F, Altini C, Cannat\u00e0 V, Davide C et al (2025) (131)I-mIBG therapy in relapsed\/refractory neuroblastoma: a weapon from the future past. Crit Rev Oncol Hematol 207:104606","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"17_CR63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L et al (2019) Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced Pheochromocytoma or Paraganglioma. J Nucl Med 60(5):623\u2013630","journal-title":"J Nucl Med"},{"issue":"5","key":"17_CR64","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P et al (2022) EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 49(5):1682\u20131699","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"35","key":"17_CR65","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1200\/JCO.21.01839","volume":"39","author":"MF Mulcahy","year":"2021","unstructured":"Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG et al (2021) Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, International, Multicenter, Phase III Trial. J Clin Oncol 39(35):3897\u20133907","journal-title":"J Clin Oncol"},{"issue":"12","key":"17_CR66","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP et al (2017) Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 18(12):1624\u20131636","journal-title":"Lancet Oncol"},{"issue":"19","key":"17_CR67","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J et al (2018) SIRveNIB: selective internal radiation therapy versus Sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 36(19):1913\u20131921","journal-title":"J Clin Oncol"},{"issue":"1","key":"17_CR68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T et al (2021) Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 6(1):17\u201329","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"17_CR69","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T et al (2024) Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med 65(2):264\u2013269","journal-title":"J Nucl Med"},{"issue":"9","key":"17_CR70","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19(9):589\u2013608","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"17_CR71","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.3390\/ijms241411626","volume":"24","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O (2023) Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci 24(14):11626","journal-title":"Int J Mol Sci"},{"issue":"5","key":"17_CR72","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/ml300410d","volume":"4","author":"K Jansen","year":"2013","unstructured":"Jansen K, Heirbaut L, Cheng JD, Joossens J, Ryabtsova O, Cos P et al (2013) Selective inhibitors of fibroblast activation protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. ACS Med Chem Lett 4(5):491\u2013496","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"17_CR73","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W et al (2019) (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60(6):801\u2013805","journal-title":"J Nucl Med"},{"issue":"3","key":"17_CR74","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J et al (2022) Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results. J Nucl Med 63(3):415\u2013423","journal-title":"J Nucl Med"},{"key":"17_CR75","first-page":"241162","volume":"65(supplement 2","author":"D Juneau","year":"2024","unstructured":"Juneau D, Kavan P, Metser U, Abikhzer G, Bodei L, Liberman M et al (2024) FRONTIER: FAPi Radioligand OpeN-label, phase 1 study to evaluate safety, Tolerability and dosImetry of [Lu-177]-PNT6555; a dose Escalation study for tReatment of patients with select solid tumors. J Nucl Med 65(supplement 2):241162","journal-title":"J Nucl Med"},{"issue":"12","key":"17_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108541","volume":"26","author":"L Greifenstein","year":"2023","unstructured":"Greifenstein L, Gunkel A, Hoehne A, Osterkamp F, Smerling C, Landvogt C et al (2023) 3BP-3940, a highly potent FAP-targeting peptide for theranostics - production, validation and first in human experience with Ga-68 and Lu-177. iScience 26(12):108541","journal-title":"iScience"},{"issue":"1","key":"17_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.107.07108","volume":"60","author":"RT Jensen","year":"2008","unstructured":"Jensen RT, Battey JF, Spindel ER, Benya RV, International Union of Pharmacology. LXVIII (2008) Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 60(1):1\u201342","journal-title":"Pharmacol Rev"},{"issue":"4","key":"17_CR78","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","volume":"20","author":"L Baratto","year":"2018","unstructured":"Baratto L, Jadvar H, Iagaru A (2018) Prostate cancer theranostics targeting gastrin-releasing peptide receptors. Mol Imaging Biol 20(4):501\u2013509","journal-title":"Mol Imaging Biol"},{"key":"17_CR79","first-page":"S221-S","volume":"34","author":"LFM Bodei","year":"2007","unstructured":"Bodei LFM, Nunn A, Llull J, Cremonesi M, Martano L, Laurora G, Scardino E, Tiberini S, Bufi G, Eaton S, de Cobelli O, Paganelli G (2007) Lu-177-AMBA Bombesin analogue in hormone refractory prostate cancer patients: a phase i escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging 34:S221-S","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"17_CR80","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","volume":"47","author":"J Kurth","year":"2020","unstructured":"Kurth J, Krause BJ, Schwarzenb\u00f6ck SM, Bergner C, Hakenberg OW, Heuschkel M (2020) First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [(177)Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 47(1):123\u2013135","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"17_CR81","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","volume":"49","author":"AK Buck","year":"2022","unstructured":"Buck AK, Serfling SE, Lindner T, H\u00e4nscheid H, Schirbel A, Hahner S et al (2022) CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging 49(12):4133\u20134144","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"17_CR82","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Herrmann K, Schirbel A, H\u00e4nscheid H, L\u00fcckerath K, Schottelius M et al (2017) CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. Theranostics 7(6):1589\u20131597","journal-title":"Theranostics"},{"issue":"7","key":"17_CR83","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-21-1533","volume":"28","author":"KM Tully","year":"2022","unstructured":"Tully KM, Tendler S, Carter LM, Sharma SK, Samuels ZV, Mandleywala K et al (2022) Radioimmunotherapy targeting Delta-like Ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity. Clin Cancer Res 28(7):1391\u20131401","journal-title":"Clin Cancer Res"},{"issue":"8","key":"17_CR84","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","volume":"25","author":"S Tendler","year":"2024","unstructured":"Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ et al (2024) Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial. Lancet Oncol 25(8):1015\u20131024","journal-title":"Lancet Oncol"},{"issue":"6","key":"17_CR85","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.7150\/thno.94788","volume":"14","author":"G Belge Bilgin","year":"2024","unstructured":"Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP et al (2024) Theranostics and artificial intelligence: new frontiers in personalized medicine. Theranostics 14(6):2367\u20132378","journal-title":"Theranostics"},{"issue":"6","key":"17_CR86","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S1470-2045(24)00037-8","volume":"25","author":"AM Scott","year":"2024","unstructured":"Scott AM, Zeglis BM, Lapi SE, Scott PJH, Windhorst AD, Abdel-Wahab M et al (2024) Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. Lancet Oncol 25(6):e250\u2013e2e9","journal-title":"Lancet Oncol"},{"issue":"11","key":"17_CR87","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","volume":"25","author":"M Abdel-Wahab","year":"2024","unstructured":"Abdel-Wahab M, Giammarile F, Carrara M, Paez D, Hricak H, Ayati N et al (2024) Radiotherapy and theranostics: a Lancet Oncology Commission. Lancet Oncol 25(11):e545\u2013ee80","journal-title":"Lancet Oncol"},{"issue":"6","key":"17_CR88","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","volume":"25","author":"F Giammarile","year":"2024","unstructured":"Giammarile F, Paez D, Zimmermann R, Cutler CS, Jalilian A, Korde A et al (2024) Production and regulatory issues for theranostics. Lancet Oncol 25(6):e260\u2013e2e9","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"17_CR89","first-page":"82s","volume":"48","author":"J Czernin","year":"2020","unstructured":"Czernin J, Calais J (2020) Nuclear medicine, molecular imaging, and theranostics: the future is bright. J Nucl Med Technol 48(Suppl 1):82s\u201383s","journal-title":"J Nucl Med Technol"}],"container-title":["Recent Results in Cancer Research","Molecular Imaging in Oncology - Volume 2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-21415-7_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:02:45Z","timestamp":1779361365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-21415-7_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032214140","9783032214157"],"references-count":89,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-21415-7_17","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"22 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}